EcoDrugPlus

5-Hydroxytryptamine Receptor 2a-Like

Ensembl ID : ENSSFOG00015030596
Gene Symbol: LOC108934223
2 Cross references
155 Possible Orthologues:

5-Hydroxytryptamine Receptor 2b

Ensembl ID : ENSSFOG00015026796
Gene Symbol: HTR2B
3 Cross references
202 Possible Orthologues:

5-Hydroxytryptamine Receptor 2b

Ensembl ID : ENSSFOG00015008356
Gene Symbol: HTR2B
3 Cross references
135 Possible Orthologues:

5-Hydroxytryptamine Receptor 2c-Like

Ensembl ID : ENSSFOG00015009484
Gene Symbol: LOC108923025
3 Cross references
202 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSSFOG00015010407
Gene Symbol: HTR3A
1 Cross references
203 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSSFOG00015002661
Gene Symbol: HTR3A
1 Cross references
132 Possible Orthologues:

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSSFOG00015010373
Gene Symbol: HTR3B
1 Cross references
174 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSSFOG00015003177
Gene Symbol: HTR4
1 Cross references
200 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSSFOG00015026151
Gene Symbol: HTR5A
3 Cross references
207 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSSFOG00015004242
Gene Symbol: HTR5A
3 Cross references
207 Possible Orthologues:

5-Hydroxytryptamine Receptor 6

Ensembl ID : ENSSFOG00015007355
Gene Symbol: HTR6
1 Cross references
114 Possible Orthologues:

60s Ribosomal Protein L10-Like

Ensembl ID : ENSSFOG00015000901
Gene Symbol: LOC108939160
3 Cross references
409 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).